Rhodanine (2-thioxothiazolidin-4-one) class of compounds as inhibitors By Tyr-OH Hydrogen Bonding Activation;
Abstract
Enoyl acyl carrier protein (ACP) reductase,
one of the enzymes of the type II fatty acid biosynthesis pathway,
has been established as a promising target for the development of new drugs for malaria.
Here we present the discovery of a rhodanine (2-thioxothiazolidin-4-one) class of compounds as inhibitors of this enzyme using a combined approach of rational selection of compounds for screening, analogue search, docking studies, and lead optimization.
The most potent inhibitor exhibits an IC50 of 35.6 nM against Plasmodium falciparum enoyl ACP reductase (PfENR) and inhibits growth of the parasite in red blood cell cultures at an IC50 value of 750 nM.
Many more compounds of this class were found to inhibit PfENR at low nanomolar to low micromolar concentrations, expanding the scope for developing new antimalarial drugs. The structure−activity relationship of these rhodanine compounds is discussed.
Citing Articles
View all 23 citing articlesCitation data is made available by participants in CrossRef's Cited-by Linking service. For a more comprehensive list of citations to this article, users are encouraged to perform a search in SciFinder.
This article has been cited by 4 ACS Journal articles (4 most recent appear below).
Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease
Bruno Bulic, Marcus Pickhardt, and Eckhard MandelkowJournal of Medicinal Chemistry2013 56 (11), 4135-4155Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease
BrunoBulic, MarcusPickhardt, and EckhardMandelkowJournal of Medicinal Chemistry2013 56 (11), 4135-4155Pharmacological approaches directed toward Alzheimer disease are diversifying in parallel with a growing number of promising targets. Investigations on the microtubule-associated protein tau yielded innovative targets backed by recent findings about the ...
Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes
Jeffrey L. Romine, Denis R. St. Laurent, John E. Leet, Scott W. Martin, Michael H. Serrano-Wu, Fukang Yang, Min Gao, Donald R O’Boyle, II, Julie A. Lemm, Jin-Hua Sun, Peter T. Nower, Xiaohua (Stella) Huang, Milind S. Deshpande, Nicholas A. Meanwell, and Lawrence B. SnyderACS Medicinal Chemistry Letters2011 2 (3), 224-229Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes
Jeffrey L.Romine, Denis R.St. Laurent, John E.Leet, Scott W.Martin, Michael H.Serrano-Wu, FukangYang, MinGao, Donald RO’Boyle, II, Julie A.Lemm, Jin-HuaSun, Peter T.Nower, Xiaohua (Stella)Huang, Milind S.Deshpande, Nicholas A.Meanwell, and Lawrence B.SnyderACS Medicinal Chemistry Letters2011 2 (3), 224-229The iminothiazolidinone BMS-858 (2) was identified as a specific inhibitor of HCV replication in a genotype 1b replicon assay via a high-throughput screening campaign. A more potent analogue, BMS-824 (18), was used in resistance mapping studies, which ...
New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
Jonathan B. Baell and Georgina A. HollowayJournal of Medicinal Chemistry2010 53 (7), 2719-2740New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays
Jonathan B.Baell and Georgina A.HollowayJournal of Medicinal Chemistry2010 53 (7), 2719-2740This report describes a number of substructural features which can help to identify compounds that appear as frequent hitters (promiscuous compounds) in many biochemical high throughput screens. The compounds identified by such substructural features are ...
Synthesis and Antimicrobial Properties of Novel Silver/Polyrhodanine Nanofibers
Hyeyoung Kong and Jyongsik JangBiomacromolecules2008 9 (10), 2677-2681
0 件のコメント:
コメントを投稿